论文部分内容阅读
目的：深入探讨沙美特罗替卡松联合家庭氧疗治疗稳定期慢性阻塞性肺疾病(COPD)的临床效果。方法41例稳定期COPD患者,患者均接受沙美特罗替卡松联合家庭氧疗治疗,评估患者接受治疗后的肺功能[第1秒用力呼气量/用力肺活量(FEV1/FVC)、第1秒用力呼气量(FEV1)以及用力肺活量(FVC)]、动脉血气变化[动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)、动脉血氧饱和度(SaO2)],并与治疗前进行比较,观察患者不良反应情况。结果①肺功能指标：所有患者治疗后FEV1为(3.1±0.3)L,高于治疗前的(2.6±0.5)L,差异具有统计学意义(t=5.4906,P=0.0000<0.05)；治疗后FVC为(1.7±0.3)L,高于治疗前的(1.4±0.4)L,差异具有统计学意义(t=3.8419,P=0.0002<0.05)；治疗后FEV1/FVC为(52.4±5.3)%,高于治疗前的(43.3±5.1)%,差异具有统计学意义(t=7.9220,P=0.0000<0.05)。②动脉血气指标：所有患者治疗后PaO2为(79.1±6.2)mm Hg(1 mm Hg=0.133 kPa),高于治疗前的(66.4±6.9)mm Hg,差异具有统计学意义(t=8.7664,P=0.0000<0.05)；治疗后PaCO2为(54.3±5.7)mm Hg,低于治疗前的(67.1±5.3)mm Hg,差异具有统计学意义(t=10.5302,P=0.0000<0.05)；治疗后SaO2为(94.2±5.2)%,高于治疗前的(87.0±5.1)%,差异具有统计学意义(t=6.3297,P=0.0000<0.05)。③不良反应情况：本组41例患者,在治疗过程中共计4例患者出现鼻喉部干燥,程度均比较轻,给予对症处理后,不良反应消失；未出现程度较为严重的不良反应。结论在稳定期COPD的治疗中使用沙美特罗替卡松联合家庭氧疗具有较好的临床效果,方法值得在临床实践中予以借鉴和推广。“,”Objective To thoroughly investigate clinical effect by salmeterol and fluticasone propionate combined with family oxygen therapy in the treatment of stable chronic obstructive pulmonary disease (COPD). MethodsA total of 41 patients with stable COPD all received salmeterol and fluticasone propionate combined with family oxygen therapy. Evaluation was made on pulmonary function [forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC), forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC)] and arterial blood gas changes[arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2) and arterial oxygen saturation (SaO2)] after treatment to compare with those before treatment, along with observation made for adverse reactions in patients.Results ①Pulmonary function index: all patients had FEV1 after treatment as (3.1±0.3)L, which was higher than (2.6±0.5)L before treatment, and the difference had statistical significance (t=5.4906,P=0.0000<0.05). Their FVC after treatment was higher as (1.7±0.3)L than (1.4±0.4)L before treatment, and the difference had statistical significance (t=3.8419,P=0.0002<0.05). Their FEV1/FVC after treatment was higher as (52.4±5.3)% than (43.3±5.1)% before treatment, and the difference had statistical significance (t=7.9220,P=0.0000<0.05). ②Arterial blood gas index: all patients had PaO2 after treatment as (79.1±6.2)mm Hg (1 mm Hg=0.133 kPa), which was higher than (66.4±6.9) mm Hg before treatment, and the difference had statistical significance (t=8.7664,P=0.0000<0.05). Their PaCO2 after treatment was lower as (54.3±5.7)mm Hg than (67.1±5.3)mm Hg before treatment, and the difference had statistical significance (t=10.5302,P=0.0000<0.05). Their SaO2 was higher after treatment as (94.2±5.2)% than (87.0±5.1)% before treatment, and difference had statistical significance (t=6.3297,P=0.0000<0.05). ③Adverse reactions: Among 41 patients, there were 4 cases with mild nasal and laryngeal dry during treatment, which were relieved by symptomatic treatment. There was no case with severe adverse reactions.Conclusion Implement of salmeterol and fluticasone propionate combined with family oxygen therapy contains excellent clinical effect in treating stable COPD, and this method is worth referring and promoting in clinical practice.